The vaccine and biotechnology company Abera Bioscience has decided to carry out a directed new share issue of approximately SEK 10 million before issue costs. This is stated in a press release.The share issue is directed to the professional investor Göran Ofsén and comprises up to 1.86 million shares. This corresponds to dilution of approximately 9.12 percent of the number of shares and votes. The subscription price is SEK 5.35 per share.According to the company, it was Ofsén himself who, on his own initiative, chose to invest in the company."Abera’s vaccine candidates could potentially save millions of lives, and I see very good opportunities for Abera to achieve a major impact primarily with its nasal vaccines," says Ofsén, who previously worked as an equity analyst and is the author of the book "Börsens framtida guldägg".The share issue is said to strengthen Abera’s financial position and create greater flexibility for the company’s continued development."This capital injection enables a faster pace of development in several of our research projects and helps ensure resources for our priority activities," says CEO Maria Alriksson.